Clinical Trials Logo

Constriction, Pathologic clinical trials

View clinical trials related to Constriction, Pathologic.

Filter by:

NCT ID: NCT05761483 Recruiting - Biliary Stricture Clinical Trials

Endoscopic Management of Non-anastomotic Biliary Strictures Following Liver Transplantation.

STEBINANSIED
Start date: March 12, 2020
Phase:
Study type: Observational [Patient Registry]

The study will evaluate the results of endoscopic treatment of NON-anastomotic biliary strictures following liver transplantation

NCT ID: NCT05750927 Completed - Clinical trials for Coronary Artery Disease

Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

ASCOP
Start date: December 1, 2022
Phase:
Study type: Observational

To describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI

NCT ID: NCT05741086 Recruiting - Clinical trials for Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

EAST-ICAS
Start date: April 15, 2023
Phase: Phase 3
Study type: Interventional

The primary goal of the trial is to investigate whether the experimental arms (receiving the Proprotein Convertase Subtilisin-Kexin Type 9 [PCSK9] inhibitor Evolocumab plus statin) could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 1 year of follow-up, compared with the control arm (taking statin) in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

NCT ID: NCT05734157 Active, not recruiting - Clinical trials for Femoral Artery Occlusion

CVT-SFA First in Human Trial for Treatment of Superficial Femoral Artery or Proximal Popliteal Artery

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.

NCT ID: NCT05726604 Recruiting - Breast Cancer Clinical Trials

4D CT Scan Versus 3D CT Scan Concerning Cardiac Dosimetry Assesment for Left Sided Breast Cancers Radiotherapy

RD3D4
Start date: March 2, 2023
Phase: N/A
Study type: Interventional

To establish if the cardiac radiation dose assesment is well aproximated with routine 3D CT scan compared to 4D CT experimental scan with respiratory gating (breath motion monitoring). The study population relates to left side breast cancers female patients that require a radiation therapy treatment.

NCT ID: NCT05724836 Recruiting - Clinical trials for Patients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery Plaque

Prospective Carotid Artery Stenosis Trial

Start date: April 12, 2023
Phase:
Study type: Observational [Patient Registry]

Researchers are collecting information and blood from subjects undergoing carotid artery interventions.

NCT ID: NCT05716659 Not yet recruiting - CVD Clinical Trials

EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.

Start date: May 30, 2023
Phase:
Study type: Observational

The specific objectives and methods of this project are: (1) To test the feasibility and accuracy of integrating EEG, MECG and EMG for detecting the severity of diseases such as aortic stenosis, heart failure and ischemic stroke. (2) Improve the accuracy of this multi-channel brain-heart-muscle device by using an artificial intelligence auxiliary system. (3) Provide tailor-made interdisciplinary treatment strategies for patients with different disease states.

NCT ID: NCT05714293 Enrolling by invitation - Clinical trials for Aortic Valve Stenosis

CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement.

CORONATE
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The goal of this interventional, single-center study is to demonstrate if there is a change in the coronary ostia height after surgical aortic valve replacement and if it depends on the type of prosthesis or surgical technique used. The study involves patients undergoing elective surgical aortic valve replacement with a bioprosthesis. Participants enrolled will undergo a CT scan before and after surgery (at least 90 days after surgery) to analyze coronary ostia height.

NCT ID: NCT05712161 Active, not recruiting - Aortic Stenosis Clinical Trials

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

DurAVR™ EFS
Start date: August 7, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and feasibility of DurAVR™ THV System in the treatment of subjects with symptomatic severe native aortic stenosis.

NCT ID: NCT05711186 Recruiting - Clinical trials for Aortic Valve Stenosis

Structured Shared Decision Making for Patients Undergoing SAVR or TAVR

TOGETHER
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

Transcatheter aortic valve replacement (TAVR) is a well-established alternative to surgical aortic valve replacement (SAVR) for the treatment of patients with severe aortic stenosis regardless of surgical risk. While TAVR and SAVR share some of the benefits and risks, they importantly differ with regards to invasiveness, time to recovery, hemodynamics, as well as options for re-intervention and possibly valve durability. An early benefit of TAVR may be offset by late risks. Therefore, current guidelines of the European Society of Cardiology recommend an integration of patient values and preferences for the selection of the treatment modality. The objective of the TOGETHER trial is to investigate the efficacy of a structured shared decision making approach (SDM) to improve patient-centered outcomes for the choice between SAVR and TAVR. TOGETHER is an investigator-initiated, randomized, open-label, single-center clinical trial. A total of 140 patients referred for treatment of symptomatic severe aortic stenosis and deemed to undergo TAVR or SAVR according to heart team decision will be randomized in a 1:1 ratio to structured SDM or usual care.